Jeremy Kortmansky, MD

• Abhijit Patel
• Anne Chiang
• Daniel Boffa
• Daniel Zelterman
• Fangyong Li
• Geliang Gan
• Harold Tara
• Henry S. Park
• Jane Kanowitz
• Jay Pahade
• Jill Lacy
• Kerin Adelson
• Kimberly L. Johung
• Michael Cecchini
• Neal Fischbach
• Pamela Kunz
• Patricia LoRusso
• Roy H. Decker
• Sajid A Khan
• Stacey Stein
• Stuart Seropian
• Terri Parker
• Wajih Kidwai
• Yanhong Deng

Gastrointestinal Diseases; Pancreatic Neoplasms; Colorectal Neoplasms

• Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
• Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D.Kim R, Tehfe M, Kavan P, Chaves J, Kortmansky J, Chen E, Lieu C, Wong L, Fakih M, Spencer K, Zhao Q, Predoiu R, Li C, Carpenter D, Leconte P, Chiorean E. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Journal Of Clinical Oncology 2022, 40: 3521-3521. DOI: 10.1200/jco.2022.40.16_suppl.3521.
• Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.Chen E, Kavan P, Tehfe M, Kortmansky J, Sawyer M, Chiorean E, Lieu C, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Carpenter D, Leconte P, Kim R. Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E. Journal Of Clinical Oncology 2022, 40: 3573-3573. DOI: 10.1200/jco.2022.40.16_suppl.3573.
• Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
• Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection.Mbewe A, Pike P, Lewis R, Kortmansky J, Chiang A, Kanowitz J. Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection. Journal Of Clinical Oncology 2021, 39: 209-209. DOI: 10.1200/jco.2020.39.28_suppl.209.
• Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasiasBranagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.
• A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancerCecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer Cancer 2020, 127: 1417-1424. PMID: 33351187, PMCID: PMC8085021, DOI: 10.1002/cncr.33379.
• Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysisMiccio JA, Talcott WJ, Patel T, Park HS, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, Jabbour SK, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis Clinical And Translational Radiation Oncology 2020, 27: 15-23. PMID: 33392398, PMCID: PMC7772693, DOI: 10.1016/j.ctro.2020.12.003.
• Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal Of Clinical Oncology 2020, 38: 4317-4345. PMID: 33197225, DOI: 10.1200/jco.20.02672.
• 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRCManji G, Bahary N, Chung V, Dalenc F, Ducreux M, Gomez-Roca C, Im S, Kortmansky J, Lacy J, Segal N, Tredan O, Cirovic O, DuPree K, Lenain C, Lu D, Robert L, Xu J, Zhang X, Kim S. 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC 2020, a157-a158. DOI: 10.1136/jitc-2020-sitc2020.0259.
• Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database AnalysisMiccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
• The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic CancerMiccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
• Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient OutcomeShah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel F, Bagaev A, Elemento O, Betel D, Giannakakou P, Lenz HJ. Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome Clinical Cancer Research 2020, 26: 4756-4766. PMID: 32641434, PMCID: PMC8209413, DOI: 10.1158/1078-0432.ccr-19-3920.
• Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and DKim R, Chaves J, Kavan P, Fakih M, Kortmansky J, Spencer K, Wong L, Tehfe M, Li J, Eyring A, Mayo C, Chiorean E. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D Annals Of Oncology 2020, 31: s450. DOI: 10.1016/j.annonc.2020.08.604.
• A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020, 49: 904-911. PMID: 32658074, DOI: 10.1097/mpa.0000000000001592.
• Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.Patel T, Srikumar T, Miccio J, Lacy J, Stein S, Kortmansky J, Staugaard C, Gambaccini M, Axtmayer A, Cecchini M. Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System. Journal Of Clinical Oncology 2020, 38: 769-769. DOI: 10.1200/jco.2020.38.4_suppl.769.
• 608P Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and DKim R, Chaves J, Kavan P, Fakih M, Kortmansky J, Spencer K, Wong L, Tehfe M, Li J, Lee M, Mayo C, Marinello P, Chiorean E. 608P Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D Annals Of Oncology 2019, 30: v229-v230. DOI: 10.1093/annonc/mdz246.085.
• 166P Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapyJacobs S, Sethi H, Kolveska T, George T, Shchegrova S, Tin T, Lee J, Olson A, Renner D, Kalashnikova E, Yothers G, Wolmark N, Pogue-Geile K, Srinivasan A, Kortmansky J, Louie M, Salari R, Zimmermann B, Aleshin A, Allegra C. 166P Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy Annals Of Oncology 2019, 30: v52. DOI: 10.1093/annonc/mdz239.074.
• OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative RadiationMiccio J, Cecchini M, Pahade J, Lacy J, Salem R, Johnson S, Blakaj A, Stein S, Kortmansky J, Johung K. OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e10-e11. DOI: 10.1016/s0360-3016(19)30424-9.
• Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313 Journal Of Clinical Oncology 2019, 37: jco.18.01295. PMID: 30817250, PMCID: PMC6494359, DOI: 10.1200/jco.18.01295.
• A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
• Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT.Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
• MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.Desai J, Kortmansky J, Segal N, Fakih M, Oh D, Kim K, Rahma O, Ko A, Chung H, Alsina M, Yeh K, Li S, Al-Sakaff N, Patel J, Barak H, Wang J, Zhang X, Bleul C, Cha E, Lee J. MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2019, 37: tps467-tps467. DOI: 10.1200/jco.2019.37.4_suppl.tps467.
• Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.
• Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.Hochster H, Catalano PJ, O'Dwyer PJ, Mitchell EP, Jill Cohen D, Andrew Faller B, Kortmansky JS, Mehta Kircher S, Lacy J, Lenz HJ, Verma UN, Bowen Benson A. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2018, 29 Suppl 5: v110. PMID: 32177014, DOI: 10.1093/annonc/mdy149.029.
• P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancerJohung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.
• O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A, ECOG-ACRIN. O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 Annals Of Oncology 2018, 29: v110. DOI: 10.1093/annonc/mdy149.029.
• Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Journal Of Clinical Oncology 2018, 36: 3504-3504. DOI: 10.1200/jco.2018.36.15_suppl.3504.
• A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).Ramanathan R, McDonough S, Philip P, Hingorani S, Lacy J, Kortmansky J, Thumar J, Chiorean E, Shields A, Behl D, Mehan P, Gaur R, Seery T, Guthrie K, Hochster H. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). Journal Of Clinical Oncology 2018, 36: 208-208. DOI: 10.1200/jco.2018.36.4_suppl.208.
• 2168Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168 Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.
• Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal AdenocarcinomaLi J, Yao X, Kortmansky JS, Fischbach NA, Stein S, Deng Y, Zhang Y, Doddamane I, Karimeddini D, Hochster HS, Lacy J. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma American Journal Of Clinical Oncology 2017, 40: 146-151. PMID: 25144267, DOI: 10.1097/coc.0000000000000114.
• Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC).Cecchini M, Salem R, Zaheer Kidwai W, Kortmansky J, Fischbach N, Patel A, Hochster H, Lacy J. Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Journal Of Clinical Oncology 2017, 35: 393-393. DOI: 10.1200/jco.2017.35.4_suppl.393.
• Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical TrialBranagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial Blood 2016, 128: 2139-2139. DOI: 10.1182/blood.v128.22.2139.2139.
• Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerStein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer British Journal Of Cancer 2016, 114: 737-743. PMID: 27022826, PMCID: PMC4984865, DOI: 10.1038/bjc.2016.45.
• Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.Stein S, James E, Cong X, Deng Y, Salem R, Cha C, Chang B, Hochster H, Doddamane I, Boustani A, Patel V, Kortmansky J, Li J, Staugaard C, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Journal Of Clinical Oncology 2016, 34: 395-395. DOI: 10.1200/jco.2016.34.4_suppl.395.
• Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC).Stein S, Cong X, Yao X, Hahn C, Li J, Kortmansky J, Chang B, Cha C, Salem R, Hochster H, Lacy J. Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2015, 33: e15274-e15274. DOI: 10.1200/jco.2015.33.15_suppl.e15274.
• Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).James E, Cong X, Yao X, Hahn C, Kaley K, Li J, Kortmansky J, Fischbach N, Cha C, Salem R, Stein S, Hochster H, Lacy J. Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2015, 33: 395-395. DOI: 10.1200/jco.2015.33.3_suppl.395.
• Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.
• Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC).Li J, Kortmansky J, Fischbach N, Stein S, Yao X, Hochster H, Lacy J. Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC). Journal Of Clinical Oncology 2013, 31: 4084-4084. DOI: 10.1200/jco.2013.31.15_suppl.4084.
• Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma.Li J, Kortmansky J, Saif M, Fischbach N, Ravage-Mass L, Elligers K, Hahn C, Cohenuram M, Lacy J. Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. Journal Of Clinical Oncology 2010, 28: tps203-tps203. DOI: 10.1200/jco.2010.28.15_suppl.tps203.
• A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic CancerCarvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly E. A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer Pancreatology 2009, 9: 404-409. PMID: 19451750, PMCID: PMC4053191, DOI: 10.1159/000187135.
• A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinomaDuffy A, Kortmansky J, Schwartz G, Capanu M, Puleio S, Minsky B, Saltz L, O’Reilly E, Kelsen D. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma Annals Of Oncology 2007, 19: 86-91. PMID: 17878176, DOI: 10.1093/annonc/mdm441.
• A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasDuran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond G, Arboine D, Dancey J, Aviel-Ronen S, Tsao M, Hedley D, Siu L. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas British Journal Of Cancer 2006, 95: 1148-1154. PMID: 17031397, PMCID: PMC2360568, DOI: 10.1038/sj.bjc.6603419.
• A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancerRathkopf D, Fornier M, Shah M, Kortmansky J, O’Reilly E, Winkelmann J, Balzano L, Kelsen D, Schwartz G. A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer Journal Of Clinical Oncology 2005, 23: 4096-4096. DOI: 10.1200/jco.2005.23.16_suppl.4096.
• A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancerKortmansky J, O’Reilly E, Minsky B, Puleio S, Winkelmann J, Kelsen D, Schwartz G. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer Journal Of Clinical Oncology 2005, 23: 4107-4107. DOI: 10.1200/jco.2005.23.16_suppl.4107.
• A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs)Duran I, Le L, Saltman D, Kortmansky J, Kocha W, Singh D, Pond G, Peralba J, Dancey J, Siu L. A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs) Journal Of Clinical Oncology 2005, 23: 3096-3096. DOI: 10.1200/jco.2005.23.16_suppl.3096.
• A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by FlavopiridolShah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol Clinical Cancer Research 2005, 11: 3836-3845. PMID: 15897584, DOI: 10.1158/1078-0432.ccr-04-2651.
• Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid TumorsKortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors Journal Of Clinical Oncology 2005, 23: 1875-1884. PMID: 15699481, DOI: 10.1200/jco.2005.03.116.
• Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracilKortmansky J, Sauter N, O'Reilly E, Shah M, Abou-Alfa G, Winkelmann J, Yi S, Gonen M, Kelsen D, Schwartz G. Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil Journal Of Clinical Oncology 2004, 22: 2140-2140. DOI: 10.1200/jco.2004.22.14_suppl.2140.
• A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumorsRathkopf D, Fornier M, Shah M, Kortmansky J, O'Reilly E, King A, Winkelmann J, Kelsen D, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors Journal Of Clinical Oncology 2004, 22: 3072-3072. DOI: 10.1200/jco.2004.22.14_suppl.3072.
• A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)Shah M, Kortmansky J, Gonen M, Tse A, Lefkowitz R, Kelsen D, Colevas D, Winkelman J, Yi S, Schwartz G. A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F) Journal Of Clinical Oncology 2004, 22: 4027-4027. DOI: 10.1200/jco.2004.22.14_suppl.4027.
• Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracilKortmansky J, Sauter N, O'Reilly E, Shah M, Abou-Alfa G, Winkelmann J, Yi S, Gonen M, Kelsen D, Schwartz G. Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil Journal Of Clinical Oncology 2004, 22: 2140-2140. DOI: 10.1200/jco.2004.22.90140.2140.
• A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumorsRathkopf D, Fornier M, Shah M, Kortmansky J, O'Reilly E, King A, Winkelmann J, Kelsen D, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors Journal Of Clinical Oncology 2004, 22: 3072-3072. DOI: 10.1200/jco.2004.22.90140.3072.
• A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)Shah M, Kortmansky J, Gonen M, Tse A, Lefkowitz R, Kelsen D, Colevas D, Winkelman J, Yi S, Schwartz G. A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F) Journal Of Clinical Oncology 2004, 22: 4027-4027. DOI: 10.1200/jco.2004.22.90140.4027.
• The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clinical Cancer Research 2003, 9: 6052-61. PMID: 14676132.
• Bryostatin-1: A Novel PKC Inhibitor in Clinical DevelopmentKortmansky J, Schwartz GK. Bryostatin-1: A Novel PKC Inhibitor in Clinical Development Cancer Investigation 2003, 21: 924-936. PMID: 14735696, DOI: 10.1081/cnv-120025095.
• Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.Seidman A, Portenoy R, Yao T, Lepore J, Mont E, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M, Usakewicz J, Southrada M, Houston C, McCabe M, Salvaggio R, Thaler H, Norton L. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. Journal Of The National Cancer Institute 1995, 87: 1316-22. PMID: 7544834, DOI: 10.1093/jnci/87.17.1316.